flow trial semaglutide kidney outcomes hazard ratio 0.76 nejm 2024 Effects of on Chronic Disease in Patients with Type 2 Diabetes Patients with type 2 #diabetes

This indicates that the association favoring semaglutide emerged later in follow-up, although it does not establish an effect of continuous treatment duration

Glial cells as integrators of peripheral and central signals in the regulation of energy homeostasis

The theory is that continuous high-dose GLP-1 agonist exposure can lead to partial receptor desensitization, and a brief period at a lower dose allows the receptors to upregulate

Dosage escalation is designed to minimize side effects: Wegovy: Start at 0.25 mg weekly, gradually increase every 4 weeks until the maintenance dose of 2.4 mg is reached

Southwest Family Medical

No, you dont need to see an endocrinologist